{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:55:39Z","timestamp":1793663739981,"version":"4.5.1"},"reference-count":14,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We reviewed findings from the meta-analysis and primary clinical trials assessing the efficacy of romosozumab, a monoclonal antibody targeting sclerostin, for the prevention of fractures and concluded that this agent can be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture. The romosozumab label has a boxed warning, recommending careful consideration by the treating clinician as to cardiovascular risk profile in the individual woman who might receive this agent, since clinical trial data from an active comparator study show an imbalance in serious cardiovascular adverse events between romosozumab and alendronate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa048","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T09:09:56Z","timestamp":1582016996000},"page":"587-594","source":"Crossref","is-referenced-by-count":412,"title":["Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update"],"prefix":"10.1210","volume":"105","author":[{"given":"Dolores","family":"Shoback","sequence":"first","affiliation":[{"name":"Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, Department of Medicine, San Francisco, California"},{"name":"Department of Medicine, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-8199","authenticated-orcid":false,"given":"Clifford J","family":"Rosen","sequence":"additional","affiliation":[{"name":"The Maine Medical Center Research Institute, Scarborough, Maine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M","family":"Black","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Health Network, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"The University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"issue":"5","key":"2022052023084427200_CIT0001","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022052023084427200_CIT0002","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1530\/JME-18-0176","article-title":"Novel actions of sclerostin on bone","volume":"62","author":"Holdsworth","year":"2019","journal-title":"J Mol Endocrinol."},{"issue":"16","key":"2022052023084427200_CIT0003","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"2022052023084427200_CIT0004","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"15","key":"2022052023084427200_CIT0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2022052023084427200_CIT0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2022052023084427200_CIT0007","author":"Food and Drug Administration","year":"2019"},{"key":"2022052023084427200_CIT0008","article-title":"Amgen. Evenity prescribing information. 2019; https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/evenity\/evenity_pi_hcp_english.ashx. Accessed December 3, 2019."},{"issue":"1","key":"2022052023084427200_CIT0009","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","article-title":"Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study","volume":"24","author":"Kang","year":"2013","journal-title":"Osteoporos Int."},{"issue":"5","key":"2022052023084427200_CIT0010","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1210\/jc.2019-00193","article-title":"Women\u2019s values and preferences regarding osteoporosis treatments: a systematic review","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022052023084427200_CIT0011","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"10102","key":"2022052023084427200_CIT0012","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet."},{"issue":"4","key":"2022052023084427200_CIT0013","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"issue":"7650","key":"2022052023084427200_CIT0014","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/587\/43775504\/jcem_105_3_587.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/587\/43775504\/jcem_105_3_587.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T19:09:03Z","timestamp":1653073743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/3\/587\/5739968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,18]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa048","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2020,2,18]]}}}